Please enter the email address you used to register, then we will send you a link to choose a new password
RBC Capital analyst Brian Abrahams reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and maintains $82 price...
Oppenheimer analyst Jeff Jones maintains Corbus Pharmaceuticals (NASDAQ:CRBP) with a Outperform and raises the price target ...
HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $80 pri...
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate o...